DGKI and glioblastoma: In a previous study on 50 GBM patients treated with the standard regimen, we showed that the methylation status of the diacylglycerol kinase iota gene (DGKI) promoter identified patients with MGMT-methylated tumors that responded poorly to the standard regimen [10].